10.09.2021 • NewsKemira

Kemira Hikes China ASA Capacity

Following the start of pre-engineering in May, Kemira has confirmed that it is adding extra production capacity for alkenyl succinic anhydride (ASA) sizing agent in China. The Finnish company is making a multi-million investment in a third production line at its site in Nanjing, Jiangsu province – it did not disclose capacity details.

Kemira is the leading producer and supplier of ASA in the Asia-Pacific region. We are committed to the industry and want to ensure security of supply and high-quality products in the long term, supporting our customers’ expansion plans. The capacity ramp-up will take place during 2022-2023,” said Alexander Wahl, director of the global sizing product line.

The company added that the decision to expand comes at a time when customers are concerned about current tight supply coupled with rapidly growing demand for the chemical, which is used to improve water-resistance in paper and packaging board.

In May, Kemira announced the start-up of a new dry polymer production plant in Ulsan, South Korea, which is run as a joint venture with Yongsan Chemicals. The facility produces dry polyacrylamide products, mostly for retention and drainage applications that Kemira said are critical in modern, fast paper and board production. 

Author: Elaine Burridge, Freelance Journalist

 

Following the start of pre-engineering in May, Kemira has confirmed it is...
Following the start of pre-engineering in May, Kemira has confirmed it is adding extra capacity for alkenyl succinic anhydride sizing agent in China. The company is making a multi-million investment in a third line in Nanjing, where the new capacity will ramp up during 2022-2023. (c) Kemira

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.